Login to Your Account



Regeneron Narrows Focus As VEGF Trap Speeds On

By Jennifer Boggs


Tuesday, September 27, 2005
Riding the popularity of drugs targeting vascular endothelial growth factor (VEGF), Regeneron Pharmaceuticals Inc. and partner Sanofi-Aventis Group are pushing forward with the VEGF Trap, positioning the product as a chief competitor for Avastin. (BioWord Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription